Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena and Vivus Take Divergent Paths To CRL Response

This article was originally published in The Pink Sheet Daily

Executive Summary

Lorqess and Qnexa both have received "complete responses" from FDA, but the drastically different contents of the letters have shaped divergent responses from the drugs' sponsors.
Advertisement

Related Content

Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave
FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave
Approvability Of Arena's Lorcaserin Still Unclear
Approvability Of Arena's Lorcaserin Still Unclear
Vivus' Qnexa Gets "Complete Response" Letter From FDA
FDA Issues Complete Response Letter for Arena's Lorcaserin
FDA Issues Complete Response Letter for Arena's Lorcaserin

Topics

Advertisement
UsernamePublicRestriction

Register

PS071413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel